通过小分子降低突变的亨廷可以缓解亨廷顿病的症状和进展
Anat Bahat1, Elad Itzhaki2, Benjamin Weiss2
1Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, 76100, Israel. anat.bahat@weizmann.ac.il.
EMBO molecular medicine
|February 20, 2024
概括
小分子SPI-24和SPI-77可以选择性地降低突变的亨廷丁 (Htt) 水平,为亨廷顿病 (HD) 提供了一个有前途的治疗策略. 这些化合物在没有明显副作用的小鼠模型中改善了症状,并延迟了疾病的进展.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 亨廷顿病 (HD) 是一种致命的遗传性神经退行性疾病.
- 它是由亨廷丁基因 (Htt) 中扩展的谷氨胺重复的结果,导致有毒突变蛋白质的积累.
- 目前的治疗方法可以控制症状,但不能改变疾病的进展.
研究的目的:
- 为了识别选择性降低突变Htt基因表达的小分子.
- 评估这些抑制剂在HD细胞和动物模型中的治疗潜力.
主要方法:
- 对Spt5-Pol II的小分子抑制剂进行查.
- 在HD患者衍生细胞和BACHD小鼠模型中测试SPI-24和SPI-77.
- 评估对突变Htt水平,线粒体功能,BDNF表达和行为表型的影响.
- 在小鼠中进行药理动力学研究和长期使用研究.
主要成果:
- SPI-24和SPI-77选择性地降低了HD细胞中的突变HttmRNA和蛋白质水平.
- 在BACHD小鼠中,直接带状发育减少了突变Htt,改善了线粒体功能,恢复了BDNF,改善了运动和焦虑缺陷.
- SPI证明了血液-大脑屏障的透.
- 口服或皮下注射延迟了早期阶段小鼠的疾病进展.
- 长期SPI-24治疗没有显示任何不良影响或全球基因表达变化.
结论:
- 使用小分子抑制剂选择性降低突变Htt的调节是HD的可行的治疗策略.
- SPI-24和SPI-77代表着对HD治疗有前途的候选药物.
- 这些化合物的进一步开发可能会导致亨廷顿病的有效治疗方法.
更多相关视频
11:22Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy
Published on: June 27, 2018
8.0K
10:52Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
Published on: December 10, 2021
2.5K
相关概念视频
02:30siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
01:22Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189